|Bid||499.00 x 800|
|Ask||508.88 x 1100|
|Day's range||502.05 - 503.75|
|52-week range||441.00 - 664.64|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||16.48|
|Earnings date||06 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||643.36|
When Cathie Wood talks, investors listen. The founder of Ark Invest has successfully predicted stock market stars -- one of her top holdings is Tesla. Now, here's some great news for all of us who want to follow this investment superstar's lead: Right now, you can buy three of the biggest holdings in her Ark Genomic Revolution ETF at a bargain.
Vir Biotechnology (NASDAQ: VIR) may be weeks away from commercializing its very first product. The clinical-stage biotech company and partner GlaxoSmithKline late last month requested Emergency Use Authorization (EUA) for their investigational COVID-19 treatment. In more good news, GlaxoSmithKline recently expanded its collaboration with Vir to include the development of potential treatments for respiratory viruses including influenza.
Kristen Choi, PhD, MS, RN, Assistant Professor, UCLA School of Nursing, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.